Quick ReadABBV surged 54% from its 2024 lows to $225, but $72.86 billion in debt and negative equity of -$6.6 billion keep it ...

AbbVie ABBV stock has risen roughly 12% over the past month. A key catalyst behind the increase was the company’s robust ...

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

Bristol Myers Squibb (NYSE:BMY) is the headline pharma name dividend hunters keep circling, drawn in by a 4.37% yield and a ...

Add Yahoo as a preferred source to see more of our stories on Google. North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the ...

This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

FILE - Packaging for AbbVie's drug, Humira. Humira-referenced biosimilars have been launched this year, but have thus far gained very little traction. (AP Photo/David J. Phillip, File) The blockbuster ...

Pharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. This week Humira, which treats ...

AbbVie’s ABBV rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical ...

The best-selling drug Humira (adalimumab) now faces competition in the United States after a 20-year monopoly. The first adalimumab biosimilar, Amjevita, launched in the United States this past ...